Float Short %

8.5

Margin Of Safety %

Put/Call OI Ratio

0.99

EPS Next Q Diff

-0.13

EPS Last/This Y

0.57

EPS This/Next Y

-0.05

Price

2.42

Target Price

5.31

Analyst Recom

2.11

Performance Q

77.94

Upside

-1,217.4%

Beta

1.7

Ticker: ZNTL

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ZNTL	2.91	0.14	0.38	1735
2026-01-26	ZNTL	2.81	0.14	2.58	1736
2026-01-27	ZNTL	2.92	0.39	0.01	2360
2026-01-28	ZNTL	2.56	0.35	2.63	2560
2026-01-29	ZNTL	2.5	0.48	22.93	2977
2026-01-30	ZNTL	2.44	0.63	12.69	3282
2026-02-02	ZNTL	2.5	0.93	0.05	3961
2026-02-03	ZNTL	2.82	0.92	0.13	4002
2026-02-04	ZNTL	2.56	0.92	0.05	4017
2026-02-05	ZNTL	2.21	0.91	1.99	4038
2026-02-06	ZNTL	2.38	0.95	0.00	4310
2026-02-09	ZNTL	2.39	0.95	0.00	4322
2026-02-10	ZNTL	2.4	0.95	0.00	4322
2026-02-11	ZNTL	2.43	0.95	0.00	4322
2026-02-12	ZNTL	2.35	0.95	0.00	4322
2026-02-13	ZNTL	2.4	0.95	0.00	4328
2026-02-17	ZNTL	2.36	0.95	999.99	4327
2026-02-18	ZNTL	2.4	0.95	999.99	4330
2026-02-19	ZNTL	2.53	1.01	0.62	4475
2026-02-20	ZNTL	2.42	0.99	0.06	4717
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ZNTL	2.92	34.4	-	-1.76
2026-01-26	ZNTL	2.80	34.4	-	-1.76
2026-01-27	ZNTL	2.93	34.4	-	-1.76
2026-01-28	ZNTL	2.56	34.4	-	-1.76
2026-01-29	ZNTL	2.50	34.4	-	-1.76
2026-01-30	ZNTL	2.44	5.9	-	-1.76
2026-02-02	ZNTL	2.51	5.9	-	-1.76
2026-02-03	ZNTL	2.82	5.9	-	-1.76
2026-02-04	ZNTL	2.55	5.9	-	-1.76
2026-02-05	ZNTL	2.21	5.9	-	-1.76
2026-02-06	ZNTL	2.38	5.9	-	-1.76
2026-02-09	ZNTL	2.39	5.9	-	-1.76
2026-02-10	ZNTL	2.40	5.9	-	-1.76
2026-02-11	ZNTL	2.43	5.9	-	-1.76
2026-02-12	ZNTL	2.34	5.9	-	-1.76
2026-02-13	ZNTL	2.39	5.9	-	-1.76
2026-02-17	ZNTL	2.37	5.9	-	-1.76
2026-02-18	ZNTL	2.41	5.9	-	-1.76
2026-02-19	ZNTL	2.53	5.9	-	-1.76
2026-02-20	ZNTL	2.42	5.9	-	-1.76
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ZNTL	-4.23	-18.73	8.44
2026-01-26	ZNTL	-4.23	-18.74	8.44
2026-01-27	ZNTL	-4.23	-18.74	8.44
2026-01-28	ZNTL	-4.23	-18.74	9.92
2026-01-29	ZNTL	-4.23	-18.74	9.92
2026-01-30	ZNTL	-4.23	-18.74	9.92
2026-02-02	ZNTL	-4.23	-18.85	9.92
2026-02-03	ZNTL	-4.23	-18.85	9.92
2026-02-04	ZNTL	-4.23	-18.85	9.92
2026-02-05	ZNTL	-4.24	-18.85	9.92
2026-02-06	ZNTL	-4.24	-18.85	9.92
2026-02-09	ZNTL	-4.24	-19.03	9.92
2026-02-10	ZNTL	-4.24	-19.03	9.92
2026-02-11	ZNTL	-4.44	-19.03	8.27
2026-02-12	ZNTL	-4.44	-19.03	8.27
2026-02-13	ZNTL	-4.44	-19.03	8.27
2026-02-17	ZNTL	-4.44	-18.33	8.27
2026-02-18	ZNTL	-4.44	-18.33	8.27
2026-02-19	ZNTL	-4.44	-18.33	8.27
2026-02-20	ZNTL	-4.44	-18.33	8.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.37

Avg. EPS Est. Current Quarter

-0.4

Avg. EPS Est. Next Quarter

-0.5

Insider Transactions

-4.44

Institutional Transactions

-18.33

Beta

1.7

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.2

Max Drawdown 5-Year %

-98.8

Target Price

5.31

P/E

Forward P/E

PEG

P/S

6.51

P/B

0.69

P/Free Cash Flow

EPS

-2.08

Average EPS Est. Cur. Y

-1.76

EPS Next Y. (Est.)

-1.81

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-555.8

Relative Volume

1.03

Return on Equity vs Sector %

-88.1

Return on Equity vs Industry %

-70.6

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.2

EBIT Estimation

Zentalis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 166

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today

news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance

stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market

stock prices ZNTL premarket after hours

ticker ZNTL fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ZNTL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y